Humacyte, Inc. 8-K

What Happened
Humacyte, Inc. announced on June 10, 2026 that it entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC (as representatives of the underwriters) to sell 47,619,048 shares of its common stock at $1.05 per share. The company granted the underwriters a 30‑day option to buy up to an additional 7,142,857 shares at the same price. The offering is expected to close on or about June 12, 2026 and is being made under the company’s effective Form S-3 shelf registration.

Key Details

• Shares offered: 47,619,048 Firm Shares at $1.05 per share.
• Underwriter option: 30‑day option to purchase up to 7,142,857 Option Shares (15% of the Firm Shares).
• Estimated net proceeds: ~ $46.80 million to Humacyte after fees/expenses; ~ $53.85 million if the option is fully exercised.
• Underwriters & filings: Representatives are Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC; underwriting agreement and legal opinion (Covington & Burling LLP) are filed as exhibits; press releases dated June 10, 2026 announced the offering and pricing.

Why It Matters
This offering will provide Humacyte with fresh capital (approximately $46.8M net, or up to ~$53.85M if the option is exercised), which increases the company’s cash resources. It will also increase the number of shares outstanding and thus dilute existing shareholders’ ownership percentage. Investors should watch the closing of the offering, any exercise of the underwriter option, and subsequent company disclosures about use of proceeds or impacts on financial outlook.